JP2023529095A - 高用量低体積のボツリヌス毒素による顔のシワの治療 - Google Patents

高用量低体積のボツリヌス毒素による顔のシワの治療 Download PDF

Info

Publication number
JP2023529095A
JP2023529095A JP2022573504A JP2022573504A JP2023529095A JP 2023529095 A JP2023529095 A JP 2023529095A JP 2022573504 A JP2022573504 A JP 2022573504A JP 2022573504 A JP2022573504 A JP 2022573504A JP 2023529095 A JP2023529095 A JP 2023529095A
Authority
JP
Japan
Prior art keywords
wrinkles
botulinum toxin
dose
facial
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529095A5 (enExample
Inventor
ロール ズザナ
スラーデク マイク
ガイスター トーリン
ピュルテ イレーナ
バイセンベルガー ペトラ
クライン グートルーン
Original Assignee
メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71016459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2023529095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー filed Critical メルツ・ファルマ・ゲーエムベーハー・ウント・コー・カーゲーアーアー
Publication of JP2023529095A publication Critical patent/JP2023529095A/ja
Publication of JP2023529095A5 publication Critical patent/JP2023529095A5/ja
Priority to JP2026018408A priority Critical patent/JP2026077675A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022573504A 2020-06-05 2021-06-04 高用量低体積のボツリヌス毒素による顔のシワの治療 Pending JP2023529095A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026018408A JP2026077675A (ja) 2020-06-05 2026-02-06 高用量低体積のボツリヌス毒素による顔のシワの治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20178574 2020-06-05
EP20178574.8 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026018408A Division JP2026077675A (ja) 2020-06-05 2026-02-06 高用量低体積のボツリヌス毒素による顔のシワの治療

Publications (2)

Publication Number Publication Date
JP2023529095A true JP2023529095A (ja) 2023-07-07
JP2023529095A5 JP2023529095A5 (enExample) 2024-06-03

Family

ID=71016459

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022573504A Pending JP2023529095A (ja) 2020-06-05 2021-06-04 高用量低体積のボツリヌス毒素による顔のシワの治療
JP2026018408A Pending JP2026077675A (ja) 2020-06-05 2026-02-06 高用量低体積のボツリヌス毒素による顔のシワの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026018408A Pending JP2026077675A (ja) 2020-06-05 2026-02-06 高用量低体積のボツリヌス毒素による顔のシワの治療

Country Status (13)

Country Link
US (2) US12599550B2 (enExample)
EP (2) EP4161562B1 (enExample)
JP (2) JP2023529095A (enExample)
KR (1) KR20230020961A (enExample)
CN (1) CN115666629A (enExample)
AU (1) AU2021286196A1 (enExample)
BR (1) BR112022023413A2 (enExample)
CA (1) CA3177835A1 (enExample)
ES (1) ES3013130T3 (enExample)
IL (1) IL298399A (enExample)
MX (1) MX2022014564A (enExample)
TW (1) TW202214211A (enExample)
WO (1) WO2021245223A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
TWI852454B (zh) * 2022-04-01 2024-08-11 大陸商重慶譽顏製藥有限公司 一種肉毒毒素蛋白組合物、製備方法及其應用
KR20250113431A (ko) * 2022-11-28 2025-07-25 메르츠 파마 게엠베하 운트 코. 카가아 목을 재생하기 위한 고 농도 보툴리눔 독소 치료
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1786459B1 (en) 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
LT2761065T (lt) * 2011-09-29 2018-01-10 Cellsnap, Llc Kompozicijos ir būdai toksigeniškumo testavimui
US11976110B2 (en) 2013-06-28 2024-05-07 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113133A1 (en) * 2017-12-04 2019-06-13 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DERMATOLOGIC SURGERY, vol. 33(s1), JPN6025017172, 2007, pages 51 - 59, ISSN: 0005583778 *
J DRUGS DERMATOL., vol. 15(12), JPN6025041783, 2016, pages 1544 - 1549, ISSN: 0005707389 *
JOURNAL OF COSMETIC DERMATOLOGY, vol. 6, JPN6025041781, 2007, pages 152 - 158, ISSN: 0005707388 *
MARC A. POLACCO, ET AL., AESTHETIC SURGERY JOURNAL, vol. Vol.41, No.6 NP500-NP511, JPN6026025748, 28 July 2020 (2020-07-28), ISSN: 0005887854 *

Also Published As

Publication number Publication date
EP4161562A1 (en) 2023-04-12
EP4467202A2 (en) 2024-11-27
KR20230020961A (ko) 2023-02-13
US20260144733A1 (en) 2026-05-28
MX2022014564A (es) 2022-12-15
EP4161562B1 (en) 2024-11-20
WO2021245223A1 (en) 2021-12-09
CN115666629A (zh) 2023-01-31
EP4467202A3 (en) 2025-02-19
TW202214211A (zh) 2022-04-16
CA3177835A1 (en) 2021-12-09
AU2021286196A1 (en) 2022-12-01
ES3013130T3 (en) 2025-04-11
JP2026077675A (ja) 2026-05-13
US12599550B2 (en) 2026-04-14
IL298399A (en) 2023-01-01
US20230329996A1 (en) 2023-10-19
BR112022023413A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
US12144847B2 (en) Non-protein clostridial toxin compositions
JP6140445B2 (ja) 血管の過敏反応と関連した皮膚状態を治療する方法および組成物
JP2026077675A (ja) 高用量低体積のボツリヌス毒素による顔のシワの治療
US20230158129A1 (en) Clostridial toxin - hyaluronic acid compositions
JP2015514074A (ja) 局所化学的神経麻痺薬を使用して皺を処置する方法
CN111655279A (zh) 具有高应答率和长效应持续时间的可注射的肉毒杆菌毒素制剂及其使用方法
TW202435908A (zh) 組成物及應用其之注射裝置
JP2011157331A (ja) 高用量投与が可能なボツリヌス毒素製剤
RU2835617C1 (ru) Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина
KR20230071072A (ko) 보툴리눔 독소 조성물
HK40085901A (en) High dose and low volume botulinum toxin treatment of facial wrinkles
KR20250113350A (ko) 비-복합체 보툴리눔 독소 조성물의 빠른 효력 발현 효과 및 이와 관련된 방법
HK40122667A (en) Botulinum toxin injection in platysma for lower face and neck rejuvenation
KR20250113431A (ko) 목을 재생하기 위한 고 농도 보툴리눔 독소 치료

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260212